# aTYR PHARMA INC (ATYR) · Edgar & Edgarette company card

> aTYR PHARMA (ATYR) saw revenue fall 19.1% in FY2025 to $0 million, operating margin -40856% against a -15.8% median for biological products, (no diagnostic substances), equity 72.6% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1339970 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/ATYR) · [JSON](https://www.pops4.com/boards/company/ATYR.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $190,000 |
| Revenue growth, 1 year | -19.1% |
| Revenue growth per year | — |
| Operating margin | -40856.3% (prior year -28899.6%) |
| Net margin | -39012.1% |
| Operating cash flow | −$62M |
| Capital spending | $77,000 |
| Free cash flow | −$62M |
| Cash | $11M |
| Long-term debt | — |
| Total assets | $93M |
| Total equity | $67M |
| Equity ÷ assets | 72.6% |
| Return on equity | -109.8% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -19.49 (distress zone)
- Piotroski F: 2 of 9 (weak)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative (-$62.0M in FY2025); operating loss: a margin of -40856.3% in FY2025; revenue is hard to predict: its 80% range is ±48%

## Edgarette's reading

Exposure: revenue $190K (FY2025). Experience: revenue down 19.1% on the year; operating margin -40856.3%, down from -28899.6%. Soundness: equity 72.6% of assets, return on equity -109.8%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $59K and $169K next year (method v4.1: its own 2-year record of growth weighed at 25% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $55K to $182K. A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -40856.3% against a -15.8% median; growth -19.1% against 21.4%.

Range logged 2026-09-24, receipt 06c251f32ca2d81e, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 2, latest 2026-06-08 ([filing](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000039/0001339970-26-000039-index.htm))

## Recent filings

- 8-K · filed 2026-10-27 · 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000071/0001339970-26-000071-index.htm)
- 8-K · filed 2026-10-16 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000068/0001339970-26-000068-index.htm)
- 8-K · filed 2026-09-24 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000065/0001339970-26-000065-index.htm)
- DEF 14A · filed 2026-09-11 · [filing](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000061/0001339970-26-000061-index.htm)
- 10-Q · filed 2026-08-07 · [filing](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000053/0001339970-26-000053-index.htm)
- 8-K · filed 2026-08-07 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000051/0001339970-26-000051-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001339970.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1339970

## Cite

POPS4, Edgar & Edgarette: aTYR PHARMA INC (ATYR) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/ATYR. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.